In RVNC’s BELMONT study, the 2-point response rate at 28 days was 85% in the RT002 40U arm (the dose being advanced to phase-3) and was 76% in the Botox arm—see slide #17:
Note: It is immaterial whether the response rate is measured at 30 days (in the Alphaeon trials) or at 28 days (in RVNC’s BELMONT study)—both time points should capture the maximum treatment effect.